Rockville Centre, NEW%20YORK2 Active Studies

Multiple Myeloma Clinical Trials in Rockville Centre, NEW%20YORK

Find 2 actively recruiting multiple myeloma clinical trials in Rockville Centre, NEW%20YORK. Connect with local research sites and explore new treatment options.

2
Active Trials
1
Sponsors
64
Enrolling

Recruiting Multiple Myeloma Studies in Rockville Centre

About Multiple Myeloma Clinical Trials in Rockville Centre

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 2 multiple myeloma clinical trials recruiting participants in Rockville Centre, NEW%20YORK. These studies are seeking a combined 64 participants. Research is being sponsored by Memorial Sloan Kettering Cancer Center. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Rockville Centre — FAQ

Are there multiple myeloma clinical trials in Rockville Centre?

Yes, there are 2 multiple myeloma clinical trials currently recruiting in Rockville Centre, NEW%20YORK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rockville Centre?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rockville Centre research site will contact you about next steps.

Are clinical trials in Rockville Centre free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rockville Centre studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 2 active trials in Rockville Centre are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated March 2, 2026 from ClinicalTrials.gov